Exploring impact of mutations in non-BRCA DNA damage response (DDR) and   non-DDR genes on efficacy in phase III EMBRACA study of talazoparib   (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm)   HER2-negative (HER2-) advanced breast cancer (ABC).

Document type:: Meeting Abstract
Author(s):: Litton, Jennifer Keating; Laird, Douglas; Rugo, Hope S.; Ettl, Johannes; Hurvitz, Sara A.; Martin, Miguel; Roche, Henri; Im, Young-Hyuck; Goodwin, Annabel; Blum, Joanne Lorraine; Eiermann, Wolfgang; Chen, Ying; Lanzalone, Silvana; Chelliserry, Jijumon; Czibere, Akos; Albacker, Lee A.; Frampton, Garrett M.; Mina, Lida A.
Title:: Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).
Journal title abbreviation:: J Clin Oncol
Year:: 2020
Journal volume:: 38 Suppl S
Journal issue:: 15
Print-ISSN:: 0732-183X
TUM Institution:: Frauenklinik und Poliklinik
BibTeX

Occurrences: